Sanofi and Teva to Collaborate on Inflammatory Bowel Disease Treatment
By Lalit Mishra
Pharma Deals Review: Vol 2023 Issue 10 (Table of Contents)
Published: 13 Oct-2023
DOI: 10.3833/pdr.v2023.i10.2809 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a significant move towards bolstering its autoimmune and gastroenterology disease portfolio, Sanofi has entered into a strategic collaboration with Teva Pharmaceuticals to co-develop and co-commercialise Teva’s novel anti-TL1A therapy, TEV’574, for the treatment of ulcerative colitis and Crohn's disease, in a deal that could be worth up to US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS